Original Investigation  October 10, 2022 Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021 Global Burden of Disease Long COVID Collaborators JAMA. Published online October 10, 2022. doi:10.1001/jama.2022.18931 Key Points Question  Among individuals who had symptomatic SARS-CoV-2 infection in 2020 and 2021, what prop...

Research Letter  October 19, 2022 Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial Stuart H. Cohen, Thomas J. Louie, Matthew Sims, et al JAMA. Published online October 19, 2022. doi:10.1001/jama.2022.16476 Antibiotics are necessary but often insufficient to treat recurrent Clostridioides difficile infection (rCDI) due to pe...

Original Investigation  October 22, 2022 Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection Christine Johnston, Amalia Magaret, Hyunju Son, et al JAMA. Published online October 22, 2022. doi:10.1001/jama.2022.19061 Key Points Question  What are the rates of viral shedding after first-episode genital herpes simplex virus type 1 (HSV-1) infection? Findings  In this prospective cohort study, 82 partic...

Original Investigation  October 21, 2022 Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial Susanna Naggie, David R. Boulware, Christopher J. Lindsell, et al JAMA. Published online October 21, 2022. doi:10.1001/jama.2022.18590 Key Points Question  Does ivermectin, 400 μg/kg, daily for 3 days, compared with placebo, shorten symptom duration among...

Research Post-acute sequelae of covid-19 six to 12 months after infection: population based study Raphael S Peter, Alexandra Nieters, Hans-Georg Kräusslich, et al BMJ 2022; 379 doi: https://doi.org/10.1136/bmj-2022-071050 (Published 13 October 2022)Cite this as: BMJ 2022;379:e071050 Abstract Objectives To describe symptoms and symptom clusters of post-covid syndrome six to 12 months after acute infection, describe risk factors, and examine the associat...

Research Letter  September 23, 2022 Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose Jessica P. Ridgway, Samuel Tideman, Thomas French, et al JAMA. 2022;328(15):1559-1561. doi:10.1001/jama.2022.17811 Vaccination with a booster dose of COVID-19 mRNA vaccine has been associated with decreased risk of developing severe COVID-19 compared with no vaccination.1,2 However, among individuals alrea...

ARTICLES| VOLUME 400, ISSUE 10360, P1334-1344, OCTOBER 15, 2022 Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial PREP-IT Investigators Lancet 2022; 400: 1334-1344 Summary Background Chlorhexidine skin antisepsis is frequently recommended for most surgical procedures; however, it is unclear if these recommendations should apply to surgery involving trau...

ARTICLES| VOLUME 400, ISSUE 10360, P1305-1320, OCTOBER 15, 2022 Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales Utkarsh Agrawal, Stuart Bedston, Colin McCowan, et al Lancet 2022; 400: 1305-1320 Summary Background Current UK vaccination policy is to offer future COVID-19...

ONLINE FIRST (FREE ACCESS) OriginalsPoor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitisDe Pascale G. et al. Development and validation of novel sepsis subphenotypes using trajectories of vital signsBhavani S.V. et al. OPEN ACCESSSmall wards in the ICU: a favorable measure for controlling the transmission of carbapenem-resistant Klebsiella pneumoniaeChi X. et al.High arterial oxygen levels ...

ORIGINAL ARTICLE FREE PREVIEW Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction Divaka Perera, Tim Clayton, Peter D. O’Kane, et al N Engl J Med 2022; 387:1351-1360DOI: 10.1056/NEJMoa2206606 Abstract BACKGROUND Whether revascularization by percutaneous coronary intervention (PCI) can improve event-free survival and left ventricular function in patients with severe ischemic left ventricular systolic dysfunction, as compared with opti...